In partnership with

Conferences

Disease Areas

Highlights from

AHA 2019

American Heart Association’s Scientific Sessions

Philadelphia, USA 16 - 18 November 2019

Articles

Introduction to the AHA Conference Report

Introduction to the AHA 2019 Conference Report

Editor Biography

New Approaches to CVD Risk Reduction

Phase 3 BETonMACE trial did not meet its primary endpoint

Inclisiran safely halves LDL-Cholesterol

Colchicine prevents cardiovascular events

Interventional Management for Acute Coronary Syndrome

Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy

Immediate coronary angiography after cardiac arrest does not improve survival

Complete revascularisation for obstructive non-culprit lesions with vulnerable plaque

Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI

Intra-aortic balloon pump better than Impella: new observational data

Results for the Ischemia Trials: To Intervene or Not to Intervene

ISCHEMIA trial: Invasive treatment only better for angina burden

Controversies in Contemporary Management of Aortic Stenosis

Full GALILEO results: Why did rivaroxaban fail after TAVR?

Balloon-expandable better than self-expanding transcatheter heart valves

RECOVERY: Benefit of early surgery in asymptomatic severe aortic stenosis

Guidelines: Updates and Controversies

New guidelines on the prevention of cardiovascular conditions

Trials in Electrophysiology and Left Ventricular Function

RENAL-AF trial: Apixaban similar to warfarin

Apple Heart Study: Not just for atrial fibrillation

Early apixaban safe as secondary prevention of stroke from AF

Carvedilol does not improve exercise performance in Fontan patients

Testosterone gel increases left ventricular mass

New Frontiers in Lipid Therapy

Icosapent ethyl plus statins reduces total plaque volume

ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients

New RNAi therapies to reduce triglycerides: 2 studies show favourable results

Targeting LDL-C <70 mg/dL is better than 100 mg/dL after stroke

Challenges in Heart Failure Management

FUEL trial: Udenafil improves some exercise measurements in Fontan

DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status

PARAGON-HF: Benefits for women and lower ejection fraction

Top image: @ iStockPhoto: Noctiluxx

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

@AHAMeetings